Author

Jennifer N. Bardos

Observed names: Bardos JN, Bardos, Jennifer N, J. Bardos, Jennifer Bardos, Jennifer N Bardos

Institution: Eli Lilly (United States)

Observed institutions: Eli Lilly (United States), King's College London, South London and Maudsley NHS Foundation Trust, King's College Hospital, Fondazione IRCCS Istituto Neurologico Carlo Besta, Wellcome Trust

OpenAlex ID: A5041938684

Trial of Galcanezumab in Prevention of Episodic Cluster Headache

2019 · Peter J. Goadsby, David W. Dodick, et al. · New England Journal of Medicine · 269

Phase 3 randomized, placebo-controlled study of galcanezumab in patients with chronic cluster headache: Results from 3-month double-blind treatment

2020 · David W Dodick, Peter J Goadsby, et al. · Cephalalgia · 163

Tolerability and safety of galcanezumab in patients with chronic cluster headache with up to 15 months of galcanezumab treatment

2021 · Miguel J. A. Láinez, Jean Schoenen, et al. · Headache The Journal of Head and Face Pain · 28

Tirzepatide Immunogenicity on Pharmacokinetics, Efficacy, and Safety: Analysis of Data From Phase 3 Studies

2023 · Garrett R Mullins, Michael E Hodsdon, et al. · The Journal of Clinical Endocrinology & Metabolism · 26

Challenges and complexities in designing cluster headache prevention clinical trials: A narrative review

2022 · David W. Dodick, Peter J. Goadsby, et al. · Headache The Journal of Head and Face Pain · 21

Treatment Outcomes in Patients Treated With Galcanezumab vs Placebo: Post Hoc Analyses From a Phase 3 Randomized Study in Patients With Episodic Cluster Headache

2020 · David Kudrow, J. Scott Andrews, et al. · Headache The Journal of Head and Face Pain · 9

Impact of Galcanezumab on Total Pain Burden: A Post Hoc Analysis of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study in Patients with Episodic Cluster Headache

2021 · J Scott Andrews, David Kudrow, et al. · Journal of Pain Research · 5

Efficacy of galcanezumab in patients with episodic cluster headaches and a history of preventive treatment failure

2021 · Brian Plato, J Scott Andrews, et al. · Cephalalgia Reports · 4

Acute and preventive treatment use in a phase-3 randomized trial of galcanezumab in chronic cluster headache

2019 · M. Lanteri-Minet, K. Kalidas, et al. · Journal of the Neurological Sciences · 3

Anti-CGRP in cluster headache therapy: a response

2020 · Richard Wenzel, Jennifer Bardos, et al. · Neurological Sciences · 2

A Placebo-Controlled Study of Galcanezumab in Patients with Episodic Cluster Headache: Results from the 8-Week Double-Blind Treatment Phase (Plen02.004)

2019 · Jennifer N. Bardos, Peter J. Goadsby, et al. · Neurology · 2

Baseline demographics and disease characteristics of patients with episodic or chronic cluster headache: data from two phase 3 randomized clinical trials in Europe and North America

2023 · Rigmor Hoejland Jensen, Cristina Tassorelli, et al. · Frontiers in Neurology · 1

Acute and Preventive Treatment Use in a Phase 3 Randomized Trial of Galcanezumab in Chronic Cluster Headache (4023)

2020 · Michel Lanteri-Minet, Kavita Kalidas, et al. · Neurology · 1

Impact of Galcanezumab on Total Pain Burden: A Post Hoc Analysis of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study in Patients with Episodic Cluster Headache

2021 · Andrews JS, Kudrow D, et al. · DOAJ (DOAJ: Directory of Open Access Journals)

Effects of Galcanezumab on Acute Medication Use, Time to Response, and Total Pain Burden in Patients with Episodic Cluster Headache: Post hoc Outcomes from a Phase 3, Randomized, Double-blind, Placebo-controlled Study (1362)

2020 · David Kudrow, J Scott Andrews, et al. · Neurology

Works count: 18

Citation count: 533

H-index: 6

I10-index: 5